RWE 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development
Australia has several real-world evidence (RWE) initiatives to support healthcare and drug development. The Therapeutic Goods Administration (TGA) has established a framework for the use of real-world data (RWD) and RWE in regulatory decision-making, which includes the use of data from electronic health records and disease registries [1]. Following the 2021 Review into the usage of RWE and patient-reported outcomes (PROs) in the regulation of medicines and medical devices, the TGA has been working on incorporating RWE and PROs into its regulatory processes [2][3][4].
Additionally, the Medicines Intelligence Centre of Research Excellence (MI-CRE) was established to generate timely research supporting the evidentiary needs of Australian medicines regulators and payers by accelerating the development and translation of RWE on medicines use and outcomes [4]. MI-CRE aims to equip the next generation of medicines researchers in Australia with the skills to co-create evidence with end-users [5].
Despite these initiatives, there are still challenges and gaps in Australia’s RWE landscape. A review on generating RWE on the quality use, benefits, and safety of medicines in Australia highlights the need for a roadmap to bolster Australia’s capacity to accelerate evidence development about the effectiveness, safety, and quality use of medicines in routine clinical care [6]. Robust RWE generation requires current data roadblocks to be remedied as a matter of urgency to deliver efficient and equitable healthcare and improve the health and well-being of all Australians [6].
References:
[1] https://globalforum.diaglobal.org/issue/may-2023/rwd-rwe-in-2023-regulatory-policy-world-tour/
[2] https://www.tga.gov.au/real-world-evidence-rwe-and-patient-reported-outcomes-pros
[4] https://www.sciencedirect.com/science/article/pii/S0149291822000170
[5] https://ijpds.org/article/view/1726
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707536/
Share this story...
Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations
RWE 201 - Lithuania – Leaping into Digital Health Future with RWE and RWD Innovations EU Partnership Agreement: https://ec.europa.eu/commission/presscorner/detail/en/ip_22_2547Lithuania is actively implementing Real-World Evidence (RWE) and Real-World Data (RWD) [...]
RWE Guest Post – Does Real-World Evidence Play a Role in G-BA’s Benefit Assessments in Germany?
RWE 201 - RWE Guest Post - Does real-world evidence play a role in G-BA's benefit assessments in Germany? Guest: Anja PownellGerman Market Access – Simplified: https://germanmarketaccesssimplified.com/IntroductionThe German [...]
RWE Guest Post – Germany – From Concept to Evaluation: The Journey of RWE requests by the G-BA
RWE 201 - RWE Guest Post – Germany - From Concept to Evaluation: The Journey of RWE requests by the G-BA Guest: Anja PownellGerman Market Access – Simplified: [...]
Spain – Championing the Ethical and Responsible Use of Real World Data
RWE 201 - Spain – Championing the Ethical and Responsible Use of Real World Data Farmindustria Code of Conduct: https://codigoprotecciondatos.farmaindustria.org/sites/medicamentosinnovadores/docs/PRODF484450.pdfIn 2022, the Spanish Data Protection Agency (AEPD) gave its [...]
EU – RWD/RWE is Embedded into the New EU Medicines Regulations
RWE 201 - EU – RWD/RWE is Embedded into the New EU Medicines Regulations Coming Soon…New EU Medicines Regulations: https://health.ec.europa.eu/medicinal-products/pharmaceutical-strategy-europe/reform-eu-pharmaceutical-legislation_enIn 2023, the European Commission undertook an ambitious overhaul of [...]
EU – EU’s Action Plan for Real-World Data (RWD) & RWE
RWE 201 - EU – EU's Action Plan for Real-World Data (RWD) & RWE The European Union has embarked on an ambitious journey to weave Real World Evidence (RWE) [...]
